Not all c-kit mutations can be corrected by imatinib
Lasota, J.
Laboratory Investigation; a Journal of Technical Methods and Pathology 87(4): 317
2007
ISSN/ISBN: 0023-6837 PMID: 17486696 Document Number: 609437
Document emailed within 1 workday
Related Documents
Shi, R.; Lin, J.; Guo, Y.; Gong, Y.P. 2014: The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells Die Pharmazie 69(5): 346-352Scheinfeld, N. 2006: Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate Journal of Drugs in Dermatology: Jdd 5(3): 228-231
Rodríguez, C.; Luis Yanes, M.I.; Delgado, M.; García Nieto, V. 2005: Failure to acidify urine in the test done with furosemide, is it a partial [corrected] resistance marker for the actions of this drug [corrected Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 25(5): 578-579
Lehman, T.A.; Bennett, W.P.; Metcalf, R.A.; Welsh, J.A.; Ecker, J.; Modali, R.V.; Ullrich, S.; Romano, J.W.; Appella, E.; Testa, J.R. 1991: P53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines Cancer Research 51(15): 4090-4096
Haarer, B.K.; Corbett, A.; Kweon, Y.; Petzold, A.S.; Silver, P.; Brown, S.S. 1996: SEC3 mutations are synthetically lethal with profilin mutations and cause defects in diploid-specific bud-site selection Genetics 144(2): 495-510
de Serres, F.J.; Overton, L.K.; Sadler, B.M. 1992: X-ray-induced specific-locus mutations in the ad-3 region of two-component heterokaryons of Neurospora crassa. XI. Heterozygous effects of gene/point mutations of genotype ad-3A or ad-3B Mutation Research 269(1): 149-169
Lang, S.M.; Heinzlmann, M.; Stratakis, D.F.; Teschauer, W.; Loeschke, K. 1997: Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis American Journal of Gastroenterology 92(12): 2166-2170
Lukin, A.A.; Planutene, M.V.; Rozov, A.N. 1983: Role of the ribosomes in controlling cell differentiation and secondary metabolism in sporulating bacteria. II. the suppression of the phenotypic expression of ribosomal mutations (strA) as affected by RNA-polymerase mutations (rfm) in Bacillus subtilis Genetika 19(5): 737-743
Rabinow, L.; Chiang, S.L.; Birchler, J.A. 1993: Mutations at the Darkener of apricot locus modulate transcript levels of copia and copia-induced mutations in Drosophila melanogaster Genetics 134(4): 1175-1185
Khalizev, A.E.; Pyzhov, A.P.; Shapiro, N.I. 1976: Development of spontaneous mutations in somatic mamalian cells and DNA replication. II. Expression of gene mutations in cultured cells Genetika 12(11): 51-60
de Serres, F.J. 1989: X-ray-induced specific-locus mutations in the ad-3 region of two-component heterokaryons of Neurospora crassa. II. More extensive genetic tests reveal an unexpectedly high frequency of multiple-locus mutations Mutation Research 210(2): 281-290
Mouroux, M.; Descamps, D.; Izopet, J.; Yvon, A.; Delaugerre, C.; Matheron, S.; Coutellier, A.; Valantin, M.A.; Bonmarchand, M.; Agut, H.; Massip, P.; Costagliola, D.; Katlama, C.; Brun-Vezinet, F.; Calvez, V. 2001: Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy Antiviral Therapy 6(3): 179-183
Chodorowski, Z.; Sein Anand, J.; Hellmann, A.; Prejzner, W. 2007: No influence of imatinib on type 2 diabetes Przeglad Lekarski 64(4-5): 370-371
Balagula, Y.; Pulitzer, M.P.; Maki, R.G.; Myskowski, P.L. 2011: Pigmentary changes in a patient treated with imatinib Journal of Drugs in Dermatology: Jdd 10(9): 1062-1066
Eckhardt, S.án. 2005: Clinical studies with imatinib in 2004 Orvosi Hetilap 146(18 Suppl 1: 941-944
Onozawa, Y.; Terashima, M. 2011: GIST refractory to imatinib treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 738-743
Lee, S.G.; Lipton, J.H. 2017: Everything old is new again: the case for imatinib as frontline therapy in 2017 Clinical Advances in Hematology and Oncology: H&o 15(4): 302-305
Heinzl, S. 2002: The tyrosine kinase antagonist imatinib mesylate Medizinische Monatsschrift für Pharmazeuten 25(1): 4-7
Balwierz, W.; Pawińska, K.; Skoczeń, S.; Klekawka, T.; Strojny, W.; Niezgoda, A. 2004: Perspectives in the use of imatinib in the treatment of childhood cancers Przeglad lekarski 61 Suppl. 2: 95-99
Durosinmi, M.A.; Salawu, L.; Lawal, O.O.; Ojo, O.S.; Alatishe, O.I.; Oyekunle, A.A.; Bolarinwa, R.A.; Adisa, A.O.; Badmos, K.; Anomneze, E.E.; Ayansanwo, A.O. 2013: Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians African Journal of Medicine and Medical Sciences 42(4): 325-332